mgdc265
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2008 (NCT00679133)
Timeline
Indications
Mechanism of action
MST1R inhibitor
- Tyrosine-protein kinase TIE-2INHIBITOR
TEK inhibitor
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Vascular endothelial growth factor receptor inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1- Mol. weight
- 517.61 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL254760 ↗
Also known as
- mgcd265
- mgcd265
- mgcd-265
- mgcd-265
- mgdc265
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02544633 | Phase 2 | Oct 1, 2015 | Mirati Therapeutics Inc. |
| NCT01930006 | Phase 1 | Aug 1, 2013 | Mirati Therapeutics Inc. |
| NCT00975767 | Phase 1 | Aug 1, 2009 | MethylGene Inc., Mirati Therapeutics Inc. |
| NCT00697632 | Phase 1 | Jun 1, 2008 | Mirati Therapeutics Inc. |
| NCT00679133 | Phase 1 | Apr 1, 2008 | MethylGene Inc., Mirati Therapeutics Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mirati Therapeutics Inc. | For profit | 5 | 5 | 2 | 2008 |
| MethylGene Inc. | For profit | 2 | 0 | 1 | 2008 |
2 organizations
Page 1 / 1